A method for detection or monitoring status of traumatic brain injury (TBI) and/or spinal cord injury (SCI) in a subject is provided. In one embodiment, the method comprises contacting a specimen of bodily fluid obtained from the subject with reagents for assaying for a marker of TBI selected from aldolase C (ALDOC) and brain lipid binding protein (BLBP/FABP7), or a trauma-specific break down product (BDP) of ALDOC or BLBP/FABP7. The method further comprises measuring the amount of marker present in the specimen as compared to a control sample, and determining the presence of TBI or SCI when an elevated amount of marker is present in the specimen compared to the control sample. Optionally, the method further comprises measuring the amount of glutamine synthetase (GS), astrocytic phosphoprotein PEA-15 (PEA15), αB-crystallin (CRYAB/HSP27), a trauma-specific proteolytic cleavage product of ALDOC, GS, PEA15, or CRYAB, or any combination of two or more thereof.

Disclosed here is a method of detecting traumatic brain injury in a subject, comprising collecting a biological sample from the subject; analyzing the biological sample to determine the level of at least one protein selected from ALDOA, PHKB, HBA-A1, DPYSL2, SYN1 and/or CKB; and determining whether the level of the at least one protein exceeds a predetermined threshold. In certain aspects, the method further comprises the step of administering a treatment to the subject if the at least one protein exceeds the predetermined threshold. The disclosed technology relates generally to brain injuries, and in particular to a panel of serum based biomarkers that can identify individuals with mild traumatic brain injury (TBI).

The present invention relates generally to methods and materials pertaining to assays, for example immunoassays, for biomarkers in body fluids e.g. blood. The invention also relates to diagnostic or screening methods for infections, and methods of differentiating between infectious and non-infectious conditions in mammals, particularly equines, for monitoring response to anti-infective/antibiotic therapy. The invention further relates to a test fluid collection system adapted to permit dilution and analysis of the collected test fluid. The invention further relates to monitoring exertional rhabdomyolysis in equines, and assay devices for all these things.

Provided herein are methods for determining whether a subject has an increased likelihood of having a disorder related to abnormal intracellular calcium store discharge. In some embodiments, the method is useful for determining whether the subject has an increased likelihood of having a neurodegenerative disease, skeletal muscle disease, cardiac muscle disease, autoimmune disease, cancer, diabetes, or has been exposed to an environmental pollutant. Kits are also provided herein.

The present invention relates generally to methods and materials pertaining to assays, for example immunoassays, for biomarkers in body fluids e.g. blood. The invention also relates to diagnostic or screening methods for infections, and methods of differentiating between infectious and non-infectious conditions in mammals, particularly equines, for monitoring response to anti-infective/antibiotic therapy. The invention further relates to a test fluid collection system adapted to permit dilution and analysis of the collected test fluid. The invention further relates to monitoring exertional rhabdomyolysis in equines, and assay devices for all these things.

Methods and devices for rapid assessment of the severity of injury not due to a natural disease based upon measurement of neutrophil gelatinase-associated lipocalin (NGAL) are provided.

Provided are methods of determining prior radiation dose exposure levels for subjects, and kits therefor. Also provided are methods of treatment.

The present invention relates to a method for mimicking the effects of ionizing radiations on cells, wherein cells are contacted with a topoisomerase inhibitor.

The present invention relates to a method for mimicking the effects of ionizing radiations on cells, wherein cells are contacted with bleomycin.

Methods for directly measuring a patient's relative sensitivity to radiation therapy are provided. In particular, the methods provide for calculating a radiation sensitivity quotient for monocytes in culture. The methods can be incorporated into radiotherapy (RT) treatment planning systems, which are also provided. The methods can be used to optimize patient treatment plans, thereby developing patient-specific radiation treatment plans. Methods for treating a patient with radiotherapy with an optimized treatment plan are provided.